This prospective study demonstrates that a simple serum blood test based on the analysis of serum glycomics can discern patients with compensated cirrhosis with a high risk for development of hepatocellular carcinoma (HCC) from patients with a low HCC risk. Screening strategies for patients with compensated cirrhosis could be guided by a positive test on GlycoCirrhoTest. This is the first biomarker that allows for a powerful risk stratification in this population. Interestingly, this biomarker is supported by a strong pathophysiological rationale. Furthermore, this technique for glycomic assessment can be easily implemented on routine capillary electrophoresis-based analysers, widely available in routine hospital laboratory facilities.
Introduction
Hepatocellular carcinoma (HCC) represents up to 85% of the primary liver cancer burden (1) . In recent years, an increasing number of biomarkers have been proposed for the diagnosis of HCC (2) . Other markers have been proposed to better assess the prognosis of the outcome of HCC (3) . However, to increase the effectiveness of screening aimed at detecting HCC at the early stage that is amenable to curative therapy, it is important to accurately identify the main risk groups. In this regard, it is well established that liver cirrhosis is the most important risk factor for HCC development. Indeed, in most prevalent aetiologies of chronic liver disease, the vast majority of HCC cases originate on a background of cirrhosis (4)(5)(6)(7), likely because hepatocellular cell proliferation in the inflammatory context of cirrhotic nodules provides a strongly enlarged pool of dividing hepatocytes in which mutagenesis can result in tumour formation. In patients with compensated cirrhosis the annual incidence of HCC ranges from 1% to 8% (8) . EASL and AASLD guidelines advocate systematic ultrasound-based screening for HCC in any patient with cirrhosis on the basis of ultrasonography (US) every 6 months(9) (10) . The aim of screening is to detect small tumours with more chance of curative therapy (11) . This screening strategy in cirrhotic patients showed a reduction in HCC mortality rates (12) and it is cost-effective (13) . Unfortunately, the proportion of cirrhosis patients who do have screening remains low. For instance, in a North American cohort, less than 20% patients with HCC reported to have received regular screening before diagnosis(14). An important reason for this is that the compensated stage of liver cirrhosis remains underdetected. The current diagnosis of compensated cirrhosis is through liver biopsy in chronic liver disease patients. However, biopsy is unsuited for regular patient monitoring and a reliable and specific non-invasive biomarker that identifies the cirrhosis-characteristic hepatocyte proliferation that predisposes to HCC development could fill this gap.
We have previously shown that the GlycoCirrhoTest, a "glycomics" biomarker based on profiling of the N-glycans from the total serum protein using capillary electrophoresis (CE), could distinguish chronic liver disease patients with compensated cirrhosis from those with earlier stages of fibrosis.
Furthermore, GlycoCirrhoTest has been optimized for use in clinical laboratories, using highthroughput DNA sequencers or CE-based analysers (15) , (16) , including those that are in use in clinical chemistry for routine serum protein electrophoresis (unpublished results).
The GlycoCirrhoTest profile of patients with cirrhosis is characterized by an increase in the proportion of bisecting N-acetylglucosamine (GlcNAc)-containing N-glycans and a decrease in the proportion of triantennary N-glycans on glycoproteins in serum (Figure 1) . The enzyme Nacetylglucosaminyltransferase III (GnT-III) catalyzes the addition of a bisecting GlcNAc residue in β1,4 linkage to the β-linked mannose of the trimannosyl core structure of N-linked oligosaccharides of glycoproteins, using UDP-GlcNAc as donor substrate (17) . This leads to the formation of the defining sugar moiety of the GlycoCirrhoTest (Figure 1 ). Neither bisecting GlcNAc residues nor GnT-III activity are detectable in a rat model in non-nodular liver tissue surrounding liver nodules or in livers of age and sex matched control rats (18) , (19) . On the other hand, in 2 different rat models of HCC (induced by 1,2-dimethyl-hydrazine or diethylnitrosamine) significant levels of GnT-III expression were observed in hepatic non-malignant cirrhotic nodules as well as in HCC nodules. Significantly increased
GnT-III activity was also observed in sera and liver tissue of patients with nodular cirrhosis and HCC but not in patients with chronic hepatitis without cirrhosis (20) , (21) . After treatment of HCC with transarterial chemoembolization or percutaneous ablation, serum GnT-III levels decreased markedly (20) , (21) . Altogether, these data suggest that GnT-III is produced in the liver in (pre)neoplastic states but not in non-cirrhotic chronic liver diseases or normal liver tissue.
Because of this biology, in the present study we had the aim of investigating the hypothesis that a high GlycoCirrhoTest value may identify those compensated cirrhosis patients with the highest risk of progressing to HCC during follow-up. For comparison, we also studied the prognostic value of FIB-4(22) and alpha foetoprotein (AFP).
Patients and methods

Study cohort
The study population consisted of 133 consecutive cirrhotic patients. Table 1 .
Glycomic analysis
Five microliter of serum were processed according to the in-solution deglycosylation method described by Vanderschaeghe et al. (15) . Briefly, denaturing buffer containing SDS was added to the serum and incubated for 5 min at 95°C. Then, the samples were treated with Peptide N-glycosidase F to release the N-glycans from their denatured carrier proteins. After enzymatic removal of the terminal sialic acid residues, the glycans were labeled with 8-aminopyrene-1,3,6-trisulphonic acid and analysed using an ABI3130 DNA sequencer as described (25) . The result of this analysis is a total serum protein electropherogram (Figure 1 ), which consists of 13 peaks. Each peak represents a wellidentified glycan (16) . The numerical height of every peak is quantified and normalised to the sum of all peak heights, thus represented as a percentage of total peak height. The GlycoCirrhoTest is calculated as the logarithmic transformation of the abundance ratio of a bigalacto core-α-1,6-fucosylated bisecting biantennary glycan (NA2FB) to a triantennary glycan (NA3) (26) .
Alpha-Foetoprotein analysis
All serum samples were diluted in 0.9% NaCl and analysed by Electro-chemiluminescence immunoassay (ECLIA) in a MODULAR E module (ROCHE).
Statistical analysis
Statistical analysis was performed using IBM © SPSS © Statistics Version 22.0. Based on a two sample ttest, mean serum levels of biomarkers were compared between patients that developed HCC and those who did not. For every marker a cox regression analysis was performed with the development of HCC as outcome variable. For cox regression analysis, an internal validation of the model was performed by applying a bias-corrected and accelerated (BCa) bootstrap (n=1000). Based on the relative change in abundance of the 6 glycans that were different (p ≤0.1) at baseline between the group of patients that developed HCC and those who did not, we designed a new composite score, the GlycoHCCRiskScore, based on multivariable logistic regression. GCT, based on two single glycans as described above, was also calculated. For both the GlycoHCCRiskScore and the GCT a ROC analysis was performed and Youden index was used to select an optimal cut-off. The patients were classified according to these cut-offs, and Cumulative Incidence (One minus cumulative survival) was calculated with the Kaplan-Meier method. Cox regression analysis was used to estimate the hazard ratio for HCC development in the biomarker-positive vs. biomarker-negative patient groups. A multivariable cox regression analysis was performed including GlycoCirrhoTest and AFP . Using the validate function of the rms package in R (version 3.2.3) cross-validation was applied to the logistic and cox regression models to adjust for the optimism in C-Index estimation. Statistical significance was set at the alpha level = 0.05.
Results
Baseline characteristics
After exclusion of patients (n=6) with a follow-up of less than 1 year and patients who developed HCC less than 1 year after enrolment (n=2), 125 patients were included for final analysis ( Figure 2 ). Among these patients, 34 (27.2%) developed HCC during follow-up after a mean interval of 66.67 months (SD 29.30). Baseline characteristics of patients who developed HCC were comparable to those who did not, except for time at risk (Table 1 ). Time at risk was defined as the duration of follow-up until appearance of HCC, liver transplantation, death or loss to follow-up. Six patients died during follow up. Three deaths were related to HCC. Time at risk was higher in the patients who did not develop HCC, compared to those who did (7.6 years vs. 5.7 years, p=0.012). However, this is inherent to the study design, as follow-up was stopped as soon as the patients developed HCC.
Association of GlycoCirrhoTest with the development of HCC
GlycoCirrhoTest is calculated as the logarithmic transformation of the ratio NA2FB to NA3 ( Figure 1) and was initially developed as a diagnostic marker for cirrhosis (26) . Baseline GlycoCirrhoTest values were significantly higher ( As illustrated in figure 4, in patients with a GlycoCirrhoTest value <0.2 at enrolment, the KaplanMeier cumulative incidence of HCC after enrolment was 23% for the complete duration of the study.
In patients with a GlycoCirrhoTest value ≥0.2 at enrolment, the cumulative incidence of HCC after enrolment was 57%. The cumulative incidence of HCC after 5, 7 and 10 years in patients with a
GlycoCirrhoTest value above or equal to 0.2 at enrolment was 22.2%, 41.9% and 57.0%. In patients with GlycoCirrhoTest below 0.2 cumulative incidence rates were respectively 3.3, 3.3 and 22.6%. It is clear from visual inspection of these curves that the predictive power for HCC risk of GlycoCirrhoTest stretches is mainly valid for a remarkably long 5-7 years upon serum sampling, upon which the discriminatory power wanes. This is confirmed using ROC analysis for HCC occurrence over different length of monitoring time upon serum sampling. In this cohort, the highest AUC values were reached for the prediction that a patient would develop HCC within the next 5-6 years ( Table 2 ). After this, the AUC trended downwards again.
Overall hazard ratio for HCC development based on Cox regression analysis was 5.05 (95% CI 2.2-11.7; p<0.001) for the total duration of the study. Taking into account only the first 7 years of follow up, the hazard ratio was 12.1 (95% CI 2.8-51.6; p=0.01).
Prognostic value of AFP, FIB-4 and other baseline biochemical variables
Mean serum AFP levels were slightly increased in the group of patients who developed HCC, as compared to the group of patients who did not (16.09 vs. 10.79 ng/ml; p=0.008). A cox regression analysis showed a significant increase of HCC risk according to baseline AFP value with a hazard ratio equal to 1.018 (95%CI: 1.005-1.031, p=0.008). A bootstrap analysis confirmed these data (p<0.001).
A ROC analysis showed an area under the curve of 0.67 (p=0.005 -95% CI 0.59-0.77) for the association with HCC occurrence (Figure 3) . Again, we defined the cut off using the Youden index.
The optimal cut off value for AFP was 5.75, yielding a sensitivity of 76% and a specificity of 55%. In patients with AFP levels below 5.75 at enrolment, the cumulative incidence of HCC was 6.4%. In patients with AFP levels above or equal to 5.75 at enrolment, the cumulative incidence of HCC was 19%. 
Total baseline glycomic fingerprint and risk for developing HCC
The blood serum N-glycan electropherogram yields 13 glycans that have been identified before (25) ( Figure 1 ). The GlycoCirrhoTest is based on only two glycans. Next, we wanted to investigate whether changes in the other 11 glycans generated in the N-glycan analysis could provide additional HCCpredictive information that was not captured by the two glycans of the GlycoCirrhoTest. In the patients who developed HCC during follow up, a significant increase in the relative abundance of NA2FB (p=0.028) and NA3Fb (p=0.023) as well as a significant decrease in the relative abundance of NA3 (p=0.01) and NA4 (p<0.001) were observed. The relative abundance of the remaining glycans did not differ significantly between both groups, although NA3Fbc (p=0.066) and NGA2FB (p=0.056)
showed a trend to increase at the α-level of 0.05 (Mann Whitney U-test throughout).
Based on the relative change in abundance of these 6 glycans that differed at baseline between the group of patients that developed HCC and those who did not (p ≤ 0.1) (Mann Whitney U) we designed a new composite score (GlycoHCCRiskScore) via logistic regression analysis. 
Discussion
Although many biomarkers have recently been developed for the diagnosis of (early) HCC(2), prognostic markers to stratify patients with compensated cirrhosis with higher and lower risk for HCC are lacking.
We here find that a simple serum glycomics-based biomarker (GlycoCirrhoTest) can be used to assess the risk for the development of HCC in patients with compensated cirrhosis. The role of the liver in the glycosylation of serum proteins is central. GlycoCirrhoTest is based on the ratio of abundance of a bisecting GlcNAc-modified N-glycan and a triantennary glycan on the total mixture of serum proteins. We previously showed that this marker could help identify patients with compensated cirrhosis among patients with chronic liver diseases, with a 79% sensitivity and a 86% specificity (26) in the discovery cohort at the statistically optimal cutoff value. At the slightly higher cutoff of 0.2 which was found in the present study to be optimal for use of GlycoCirrhoTest as an HCC risk predictor, about 50% of compensated cirrhosis cases surpass this threshold in an aggregate analysis of three independent cohorts from multiple clinical centers (total number of included chronic liver disease patients >600; manuscript in preparation). This corresponds well with the 50% cumulative long-term incidence of HCC observed in the present study for compensated cirrhosis patients with a
GlycoCirrhoTestvalue of higher than 0.2. Although these findings require further validation, this strongly indicates that GlycoCirrhoTest-based monitoring of chronic liver disease patients would reliably and non-invasively detect almost all compensated cirrhosis patients who are at real risk for HCC development. This answers a major medical need in current tools for cirrhosis and HCC monitoring.
The cut-off of 0.2 favours sensitivity above specificity, as the implications of a false positive screening results, which would lead to a supplementary imaging of the liver, is more acceptable than a false negative result. Patients who expressed a GlycoCirrhoTest above 0.2 experienced a significantly increased cumulative HCC incidence of 42% versus 3% after 7 years (p<0.001). Overall hazard ratio for HCC development based on Cox regression analysis was 5.1 (95% CI 2.2-11.7; p<0.001) for patients who had a baseline GlycoCirrhoTest higher than 0.2, and at this same cutoff the hazard ratio for HCC development within 7 years was 12.1 (95% CI 2.8-51.6; p=0.01). In contrast, AFP showed a hazard ratio of 4.65 (95% CI 1.588-13.607; p=0.005). In a multivariable cox regression model including GlycoCirrhoTest and AFP , only GlycoCirrhoTest showed a significant association with the occurrence of HCC. Similarly, the prognostic value of the whole glycomic fingerprint including all 13 glycans, as expressed in the GlycoHCCRiskScore was not superior to the value of the GlycoCirrhoTest.
Of note, all of the glycans that had higher abundance in the patients with increased HCC risk were modified with either a fucose, a bisecting GlcNAc or both, whereas the glycans with decreased abundance are the unmodified precursors. This overall glycome change is most simply and robustly captured in GlycoCirrhoTest (AUC = 0.70, which is very similar to the one of the full complexity GlycoHCCRiskScore, AUC = 0.73).
The underlying pathophysiological rationale of the GlycoCirrhoTest is partially elucidated. The enzyme responsible for the formation of bisecting GlcNAc residues, N-acetylglucosaminyltransferase III (GnT-III) is not expressed in hepatocytes in normal physiological conditions, but is increasingly expressed in rat liver dysplastic and malignant nodules during hepatocarcinogenesis (18, 19) .
Furthermore, GnT-III activity is gradually increased in sera and nodular liver tissue of cirrhotic patients without and with HCC (21) , (20) . Importantly, we previously showed that GlycoCirrhoTest is specifically increased in cirrhotic patients, but not in patients with earlier stages of liver fibrosis (26), which supports the hypothesis that GlycoCirrhoTest increase is related to upregulation of GnT-III in regenerative nodules, which are the histological hallmark of liver cirrhosis and are not present in earlier stages of liver fibrosis. It is conceivable that with more hepatocytes actively dividing in such nodules, the risk for propagation of oncogenic mutations increases and hence the risk for HCC rises.
Therefore a true marker for such nodular regeneration in liver cirrhosis should also be a good risk marker for HCC, as validated here for GlycoCirrhoTest (26) .
Alternative biomarkers for HCC risk have been proposed. FIB-4, a composite biomarker based on AST, ALT, platelet count and age, has been suggested as a prognostic marker for HCC development among chronic hepatitis C infected patients; however, this study included a majority of non-cirrhotic patients, and was not designed to assess risk within a cirrhotic cohort (27) . In contrast, our cohort included only patients with compensated cirrhosis. Within this cirrhotic population, the HCC prognostic power of FIB-4 could not be confirmed. Risk models for the prediction of HCC risk have been developed. Abu-amara et al. (28) recently perfomed an external validation of 5 risk models for HCC development and showed a good prognostic performance, especially for the identification of low risk patients. However, these models have only been developed for chronic hepatitis B patients.
It is well known that hepatitis B is an oncogenic virus with appearance of HCC before the cirrhotic stage has been reached in a larger fraction of patients (29 Current EASL and AASLD guidelines(9)(10) recommend biannual screening of cirrhotic patients with ultrasonography for the appearance of HCC, which is cost-effective as it results in the detection of more cases of HCC in a stage that can be effectively treated using existing interventions. However, such screening requires the prior diagnosis of cirrhosis, and this is often not the case for patients with early-stage, compensated cirrhosis. Inclusion of GlycoCirrhoTest in the monitoring scheme for chronic liver disease patients can fill this gap, which should ultimately lead to the detection of more HCC cases at a curable stage of the disease than is presently achievable.
Furthermore, using the 0.2 cut-off, GlycoCirrhoTest offers a high 7-year negative predictive value for HCC development of 97%, allowing for the selection of low risk patients. We might imagine that these patients could be offered a less stringent follow-up which is not only more convenient for the patients but might prove a cost-saving strategy. These observations demand a prospective validation with GlycoCirrhoTest measurement as part of the monitoring strategy for chronic liver disease patients, preferably in current standard clinical practice. The immediate utility of GlycoCirrhoTest may also be to use it as an inclusion criterion for cirrhotic patients in HCC-preventing clinical trials.
With a 12 fold increase of 7 year HCC incidence in the GlycoCirrhoTest positive group, the required number of patients for clinical trials could be very significantly reduced, saving cost and time in organising such trials. Panel A: The structures of the N-glycan peaks in the total serum of a cirrhotic patient as obtained using capillary electrophoresis yields 13 peaks. From left to right : Peak 1 is an agalacto, core-alpha-1,6-fucosylated biantennary (NGA2F), peak 2 is an agalacto, core-alpha-1,6-fucosylated bisecting biantennary (NGA2FB), peak 3 and peak 4 are single agalacto, core-alpha-1,6-fucosylated biantennary structures (NG1A2F), peak 5 is the bigalacto biantennary glycan NA2, peak 6 is the bigalacto, core-alpha-1,6-fucosylated biantennary glycan NA2F, peak 7 is the bigalacto, core-alpha-1,6-fucosylated bisecting biantennary glycan NA2FB, peak 8 is the triantennary glycan NA3, peak 9 is the branching alpha-1,3-fucosylated triantennary glycan NA3Fb, peak 9 is the core-alpha-1,6-fucosylated triantennary glycan NA3Fc, peak 10 is the branching alpha-1,3-fucosylated and core alpha-1,6-fucosylated triantennary glycan NA3Fbc, peak 11 is a tetra-antennary (NA4) and peak 12 is 
